Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Mar;37(2):209-18.
doi: 10.1016/j.cct.2013.12.006. Epub 2013 Dec 31.

Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community

Affiliations
Randomized Controlled Trial

Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community

Sandra A Springer et al. Contemp Clin Trials. 2014 Mar.

Erratum in

Abstract

Background: HIV-infected prisoners have a high prevalence of alcohol use disorders and commonly relapse to alcohol soon after release to the community which is linked to high morbidity, poor antiretroviral therapy (ART) adherence and increased sexual risk-taking behaviors. Extended-release naltrexone (XR-NTX) effectively reduces relapse to alcohol in alcohol dependent persons, yet it remains unexamined among criminal justice system (CJS) populations transitioning to the community.

Methods: A randomized double-blind, placebo-controlled trial of XR-NTX to improve HIV treatment outcomes via reducing relapse to alcohol use after prison release for HIV-infected hazardous drinking and alcohol dependent prisoners is discussed.

Results: Acceptability of study participation is high with 86% of those referred who met eligibility criteria and 85% of those who were able to receive injections prior to release accepted injections, yet important implementation issues are identified and addressed during the study and are discussed in this paper.

Conclusion: Medication-assisted therapies for prevention of relapse to alcohol use for CJS populations transitioning to the community, especially for HIV-infected patients, are urgently needed in order to reduce alcohol relapse after release and improve HIV treatment outcomes and contribute to improved individual and public health.

Trial registration: ClinicalTrials.gov NCT01077310.

Keywords: Alcohol use disorder; Extended-release naltrexone; HIV; Hazardous drinking; Prisoners; Randomized controlled trial.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study Design
Figure 2
Figure 2
Study Flow of Acceptability
Figure 3
Figure 3
Study Procedure Timeline

References

    1. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. American journal of public health. 2002;92:1789–94. - PMC - PubMed
    1. Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PloS one. 2009;4:e7558. - PMC - PubMed
    1. Mumola C. Justice UDo, editor. Substance Abuse and Treatment, State and Federal Prisoners, 1997. 1999. pp. 1–16.
    1. Serfaty L, Poujol-Robert A, Carbonell N, Chazouilleres O, Poupon RE, Poupon R. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol. 2002;97:1807–12. - PubMed
    1. Springer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. The American journal of drug and alcohol abuse. 2011;37:12–21. - PMC - PubMed

Publication types

MeSH terms

Associated data